Alternatively, heregulin genomic induction increases the phosphorylation level of HER3, providing resistance to EGFR-inhibitors in EGFR-mutated NSCLC or CRC cells [23,24]. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.